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Structure-based discovery and in-parallel optimization of novel 
competitive inhibitors of thymidylate synthase 
Donatella Tondi , l* Ursula Slomczynska It, M Paola Costi*, D Martin Wattersonl, 
Stefano Ghelli3 and Brian K Shoichetl 
Background: The substrate sites of enzymes are attractive targets for structure- 
based inhibitor design. Two difficulties hinder efforts to discover and elaborate 
new (nonsubstrate-like) inhibitors for these sites. First, novel inhibitors often 
bind at nonsubstrate sites. Second, a novel scaffold introduces chemistry that is 
frequently unfamiliar, making synthetic elaboration challenging. 
Results: In an effort to discover and elaborate a novel scaffold for a 
substrate site, we combined structure-based screening with in-parallel 
synthetic elaboration. These techniques were used to find new inhibitors that 
bound to the folate site of Lactob,scillus casei thymidylate synthase (LcTS), 
an enzyme that is a potential target for proliferative diseases, and is highly 
studied. The available chemicals directory was screened, using a molecular- 
docking computer program, for molecules that complemented the three- 
dimensional structure of this site. Five high-ranking compounds were 
selected for testing. Activity and clocking studies led to a derivative of one of 
these, dansyltyrosine (K, 65 PM). IJsing solid-phase in-parallel techniques 33 
derivatives of this lead were synthiesized and tested. These analogs are 
dissimilar to the substrate but bind competitively with it. The most active 
analog had a K, of 1.3 ,uM. The tighter binding inhibitors were also the most 
specific for LcTS versus related enzymes. 
Conclusions: TS can recognize inhibitors that are dissimilar to, but that bind 
competitively with, the folate substrate. Combining structure-based 
discovery with in-parallel synthetic techniques allowed the rapid elaboration 
of this series of compounds. More automated versions of this approach can 
be envisaged. 
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Introduction 
I f  the structure of an enzyme is available, it should be 
possible to discover new ligands that will bind to the 
enzyme and modulate its action. Enzyme active sites are 
well formed and highly functionalized, and would seem to 
be good targets for such structure-based efforts. Ideally, 
one would like to find a new ligand scaffold and then 
elaborate upon it rapidly, guided by the active-site struc- 
ture. Doing so is a current challenge in structural biology 
and medicinal chemistry. 
Progress has been made in the structure-based elabora- 
tion of known lead compounds, typically substrates or 
substrate analogs. This has involved cycles of synthesis 
and structure determination [l-3], and has also drawn 
upon computational tools [4]. R.ecently, investigators have 
combined computational and !Stl’LlctLlrd~ approaches with 
combinatorial and in-parallel syntheses for focused 
explorations of a known lea’d scaffold [S,h] resulting 
in inhibitors up to lOOO-fold more potent than the 
initial lead. 
Nonsubstrate-like inhibitors (novel inhibitors) have also 
been discovered for enzymes and receptors. This has 
been accomplished by high-throughput screening of com- 
binatorial, phage-display, natural-product and other 
libraries [7,8]. From structural studies, novel inhibitors 
have been discovered by molecular-docking screens of 
structural databases [9-121 and by de n~o design 
approaches [1,13-161. These and other [17-211 structural 
studies show how some enzymes recognize new 
inhibitors. Often, these inhibitors bind to the enzyme in 
orientations that differ from that adopted by the substrate 
or they bind to nonsubstrate sites [18,20,22-251. 
In contrast to the binding heterogeneity and chemical 
diversity of nonsubstrate-like inhibitors, the binding ori- 
entations and chemical structures’of most substrates are 
highly constrained; enzymes are highly specific for their 
substrates [26,27]. Inhibitorsthat do bind in substrate sites 
are typically substrate analogs. This might suggest a dif- 
ferential specificity between substrate and nonsubstrate 
sites for ligand chemistry or, alternatively, our notions of 
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Table 1 Figure 1 
Compounds chosen from the initial DOCK screen. 
Compound Structure IC,, (FM) Dock rank 
Insoluble* 76 
3 439 204 
4 @@+(=J 2ooo 
226 
+No activity 229 
‘Insoluble at 50 pM. +No measurable inhibition at 50 f.rM 
the specificity of substrate sites might be biased by a fore- 
knowledge of substrate structure. 
We were interested in investigating the ability of a well- 
defined substrate site to bind molecules that are dissimilar 
to the substrate. To do so, we needed an approach that 
would suggest new scaffolds that might fit the substrate 
site and allow the rapid synthetic elaboration of a lead 
inhibitor. The following approach was adopted. To suggest 
new lead compounds, we screened 153,516 compounds of 
the available chemicals directory (ACD) of commercially 
available chemicals against the X-ray crystal structure of 
thymidylate synthase (TS) from Lactobacilhs casei (LcTS) 
using the molecular-docking computer program DOCK 
[lo]. TS catalyzes the final step on the biosynthetic 
pathway to thymidylate, and is consequently a target for 
anticancer drugs in human cells, and is a potential target for 
antimicrobial chemotherapy. Moreover, TS has been 
intensely studied as a target for structure-based inhibitor 
design [15], and new inhibitors have been discovered that 
bind to the enzyme [1,18]. Methodologically, docking 
screens should be unbiased by any substrate information 
a) La224 
Phe228 
b) 
La224 1 
m 
I’ y CB3717 
Asp22 1 
dansyl 
hydrazine & 
Leu195 
Chemistry & &log) d 
(a) The orientation of dansylhydrazine from the original docking search 
(carbon, green; oxygen, red; nitrogen, blue; sulfur, yellow). Residues in 
the binding pocket defined by CB3717 are shown and labeled, as is 
dUMP (carbon in gray). Several polar and nonpolar interactions are 
shown between LcTS and the computed orientation (dashed yellow 
lines). (b) The orientation of CB3717 in the site is shown for 
comparison. This figure was generated using Neon with MidasPlus [49]. 
other than that defined by the structure of the binding site 
itself; this technique has discovered new inhibitors [lo] 
albeit ones that often bind at nonsubstrate sites 
[18,23,28,29]. The docking calculation was conducted 
against the site defined by CB3717, an analog of the sub- 
strate S,lO-methylenetetrahydrofolate (CHZ-H,folate), in 
its ternary complex structure with deoxyuridine monophos- 
phate (dUMP) and TS [30]. In this ternary complex, the 
enzyme has undergone a conformational change that closes 
down the active site on the ligands. We looked for 
inhibitors that acted competitively with the substrate in 
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Table 2 
Dansyl derivatives synthesized in liquid phase. 
Compound Isomer Y R R” R 
,,I 
IC,, (pm) 
1A 
2A 
3A 
4A 
5A 
6A 
7A 
8A 
9A 
10A 
11A 
12A 
13A 
14A 
15A 
16A 
17A 
18A 
19A 
20A+ 
21A+ 
22A+ 
S 01 
R 0 
S NH 
S 0 
S NH 
S 0 
S 0 
R 0 
S 0 
R 0 
S NH 
S 0 
R 0 
S 0 
S 0 
S 0 
S 0 
R 0 
S 0 
S 
S 
S 
COOH 
COOH 
COOH 
COOH 
COOH 
COOH 
COOH 
COOH 
CONH, 
CONH, 
CONH, 
CONH, 
CONH, 
COOH 
COOH 
CONHCH,CONH, 
CONHCH,COOH 
COOH 
COOH 
NH, 
NH2 
NH, 
‘3 
NH, 
‘3 
NHCOCH, 
NHCOCH, 
‘3 
NH, 
‘3 
NHCOCH, 
NHCOCH, 
NHBOC 
NHFMOC 
NH2 
NH, 
NHSO,-dansyl 
H 
NW&), 163 
WH,), 220 
NW,), 348 
Cl 250* 
Cl 457 
H 435 
WH,), 103 
NW&), 110* 
NW,), 83 
NW& 70 
NW,), 140* 
WH,), 253* 
NW,), 459* 
NW,), 78 
NO-Q, 108 
NW,), 196* 
NW,), 104 
NW,), 70 
NW,), 74 
409 
1900 
4200 
*I&, is approximate due to the low solubility of compound. +The entire structure is represented in the column, not just the R’ group. 
enzyme assays. To allow the rapid elaboration of any 
inhibitor discovered, we wanted a lead compound that was 
compatible with solid-phase in-parallel derivatization. 
We report here the discovery of a new class of antifolates 
that binds to LcTS at micromolar concentrations. These 
inhibitors do not resemble the :substrate or classical antifo- 
lates; nevertheless, they are competitive inhibitors of 
LcTS. In this new class of inhibitors, as affinity increases 
so too does specificity for LcTS versus related enzymes. 
Results 
A list of 400 top-scoring molecules was generated by 
DOCK on the basis of van tier Waals interactions and 
electrostatic interaction energy [31], both of which were 
corrected for ligand desolvation energy [32]. Five com- 
pounds were chosen for initial enzymatic tests from this 
list (Table 1). In addition to having a good DOCK score, 
these choices were made on the basis of the number of 
polar interactions observed in the docked complex and 
the possibility of making derivatives of a given molecule 
through solid-phase synthesis. 
. 
Of the molecules chosen, compound 1 (IC5,=300 @VI) was 
a quinazoline that resembled CB3717 and the substrate 
(several more flexible quinazolines in the ACD were 
missed in our calculation, partly because l&and flexibility 
was not allowed). The similarity of compound 1 to known 
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Figure 2 
A docked orientation of dansyltyrosine in LcTS. The molecular surface 
of the binding site is shown in gray, except for Lys50, which is shown 
in blue. Key residues are labeled. The color scheme is the same as in 
Figure 1, 
antifolates made it unappealing as a lead compound for 
this study. Compound 2 was insoluble in buffer. Com- 
pound 4 had very low affinity for LcTS and compound 5 
was inactive at its solubility limit of 50 @l. The most 
Figure 3 
interesting compound was 3, dansylhydrazine, which 
inhibited TS competitively with an I& of 439 @I, did 
not resemble known antifolates and seemed suitable for 
chemical elaboration. 
In the docked orientation, dansylhydrazine appears to 
interact with LcTS through three hydrogen bonds: ligand 
atom 014 (SOZ)-NH1 of ArgZ3 (distance 3.2 :f)i ligand 
atom 01.5 (SOZ)-NH2 of Arg23 (distance 2.8 A); and 
ligand atom NH (NH-NH2)-0 of \‘a1316 (distance 3.3 A, 
Figure 1). IVonpolar contacts are also made. This geome- 
try suggested that larger derivatives could be accommo- 
dated by the enzyme. Seven dansyl amino acid analogs, 
representing a range of sulfonyl derivatives, were tested 
against LcTS (see the Supplementary material). Among 
these, 0-dansyl-I,-tyrosine (IA in Table 2, dansyltyrosine) 
was a competitive inhibitor of LcTS with an ICTo value of 
163 /JLM and a Ki value of 65 @l. 
We explored the structural bases for the activity of dansyl- 
tyrosine. Low-energy conformations of the molecule (500) 
were calculated [33] and docked into the folate-binding 
L 
,’ 
/ j  
i DIEA 
NMP (d 
i 
J 
R SO& or 
R COCI 
Cd) 
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VW iN\ 
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Chemistry & Biology 
In-parallel solid phase synthesis of dansyltyrosine derivatives. Reagents and conditions: (a) MSNT, Melm, CH,CI,, room temperature. (b) 20% PIP, 
DMF, room temperature. (c) DIEA, NMP, room temperature. (d) TFA, CH,CI,, 2 h, room temperature. 
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Table 3 
Derivatives of dansyltyrosine synthesized in parallel. 
ov;fOO” 
I k 
Compound R Group IC,, (PM) Compound R Group IC,, (PM) 
1B 
2B 
38 
4B 
5B 
6B 
78 
88 
9B 
10B 
11B 
12B 
138 
86 14B 21 
so/2 
a 
25 158 
109 16B 
8.8 18B+ 
19B 
16.7 
68* 
20B 
67 
101 
256 
49 
161 
138 
27 
02N 
co’ 
OzN 
so’, 
20 
19 
60 
10 
4.7 
21B 3.4 
N(C”h 
co’ 
22B 70 
Qc”r 
co’ 
23B \ 34 
/ 
N 
248 N 
S’ 
10 
‘N 
H3CCONH 
25B 29 
so: 
26B >>50* 
27B >>I 005 
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Table 3 cont’d 
Derivatives of dansyltyrosine synthesized in parallel. 
ow;r 
$02 
k 
2gB 
30B 
s& 
H 
7 33B 
, 
13.5 
11 
/ 
34B F~C-CHZ-~~~ 90 
c1 
Compound 
28B 
R Group IC,, (FM) Compound 
10 328 
R Group IC,, WV 
66 
31B 53* 
N(C,H,), 
*Estimated due to low solubility of this compound. +17B was not tested because of the low reaction yield. *No activity detected at 50 PM. §No 
. activity detected at 100 PM. 
site. The resulting configurations clustered into two orien- 
tations. In one orientation, the tyrosine group overlaps the 
quinazoline ring of CB3717. In the second cluster of orien- 
tations, the dansyl sulfone group overlaps the quinazoline 
ring of CB3717, making hydrophobic contacts with the 
surrounding residues (Trp85, Trp82, dUMP, Ile81, 
Phe228 and Leu224). An apparent hydrogen bond is made 
between the carboxylate group of the tyrosine amino acid 
moiety and the NC of Lys50 (06-NC distance 2.7 A; 
07-N5 distance 2.8 A; Figure 2). 
Although we cannot distinguish between these two possi- 
bilities unambiguously, structure-activity relationships 
favor the dansyl group acting as the anchor fragment, 
binding in the quinazoline site, as suggested by the 
second cluster of orientations. For example, tyrosine 
derivatives had no inhibitory activity against TS, whereas 
dansyl derivatives were active. Molecules that changed 
the geometry around the naphthyl ring lost almost all 
activity (compounds ZlA and %A; Table 2). Converting 
the zwitterionic amino acid into a compound that bore a 
formal charge, either by acylating the amino group (com- 
pounds 7A and 8A) or by amidating the carboxylate (com- 
pounds 9A and llA), led to inhibitors with up to twofold 
improved activity. Derivatives with both substitutions 
were less active by twofold to threefold (12A and 13A). 
The amino group seemed to accommodate larger sub- 
stituents (14A and 15A) than did the carboxylic acid (16A). 
None of these observations was compelling by them- 
selves, but taken together they suggested amino deriva- 
tives of 0-dansyl-I,-tyrosine could bc favorably 
accommodated by LcTS. 
A small library of 33 amino derivatives of 0-dansyl-I,-tyro- 
sine was synthesized using solid-phase in-parallel chem- 
istry (Figure 3). These compounds inhibited LcTS with 
I&, values ranging from 3.4 to 256 @I (Table 3). The 
most potent of these compounds, iV,O-didansyl-I,-tyrosine 
(ZlB, didansyltyrosine), had a Ki of 1.3 phi. This com- 
pound was a competitive inhibitor of TS versus CHZ- 
H,folate (Figure 4) and was noncompetitive versus the 
second TS substrate, dUXIP, which binds at a second site 
(data not shown). Ten other compounds had IC,,, values 
of less than 20 @I, which, assuming competitive inhibi- 
tion, suggests that they have Ki values of less than 10 yM. 
One of these, ZOB, was explicitly shown to be competitive 
with a Ki of 1.7 phi (data not shown). 
To construct a model for how didansyltyrosine (21B) bound 
to LcTS further docking calculations were performed. Low 
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Figure 4 
IDldansyl tyros~ne] (pM) 
l:h 
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k 
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t/folate @M-J) Chemistry & Biology 
Lineweaver-Burk plot for didansyltyrosine (21 B). The concentrations 
of inhibitor used were 0 PM (open diamonds); 0.67 uM (X); 1.3 uM 
(filled diamonds); 2.6 PM (filled triangles); 5.2 pM (+). The Y axis is 
(ODa,O/min)-l. The inset shows the re-plot of the slopes, giving a K, 
of 1.3 pM. 
energy conformations of the molecule (500) were generated 
[33] and docked into the binding site. Several families of 
orientations of didansyltyrosine were found that fit the 
enzyme well. Most position the original dansyl group in the 
quinazoline site of LcTS (Figure Sa,b). In the orientation 
shown in Figure Sa, this anchor dansyl ring makes nonpolar 
interactions with the pyrimidine ring of dUMP (distances 
are C45-04 of dUMP 3.4A; C42-Nl of dUMP 4.51 A; 
C42-C6 of dUMP 4.21 A). The dansyl ring also makes non- 
polar contacts with folate-binding residues, including 
C35C@ of 11581 4.0 A, C45-NH2 of Arg23 4.0 A, C42-Cp 
of Ala315 3.9 A, and C4S-Cal of Leu19.5 4.5 A. 
As the inhibitor extends out of the quinazoline-binding 
site of LcTS, the active-site cleft opens up (Figure 6), 
leaving room for more orientations of the flexible AT-dan- 
syltyrosine group. In most orientations, the tyrosine ring 
interacts with hydrophobic residues such as Phe228 and 
Leu224. In the orientation represented in Figure Sa, for 
instance, four tyrosine-ring atoms interact with Phe228 at 
distances ranging from 3.3 to 3.8 A, and three ring atoms 
interact with Leu224 at distances ranging from 3.2 A to 
3.6 A. In this orientation, the tyrosine carboxylate main- 
tains its interaction with LysSO (022-NC of Lys50 2.8 A). 
In other high-scoring orientatilons this interaction is lost, 
and the carboxylate extends out towards the solvent. 
The conformation of the second dansyl group varies most 
in the docked orientations, falling as it does in the most 
open part of the site (Figure 6). Among the most energeti- 
cally favorable configurations is that which places this ring 
Figure 5 
Didansyltyrosine docked into the folate-binding site of LcTS (colored 
as in Figure 1). (a) The docked orientation of didansyltyrosine in LcTS. 
(b) The crystallographic structure of CB3717 in LcTS. 
SO as to interact with residues Ala309 (ligand 
C12-CD 3.2 A and ligand C6-CD 3.7 A) and Ile310 (ligand 
CB-0 3.4 A) and with Lys51 (ligdnd C17-NC 4.1 A), at the 
mouth of the active site (Figure Sa). In a second family of 
favorable conformations, the second dansyl ring packs 
against a hydrophobic patch at the mouth of the active 
site, interacting with Leu56 (3.1 A), Ile81 (3.5 A) and the 
C$l of His80 (3.2 A). In this orientation, the dimethyl 
amino group of the second dansyl ring points towards 
residues of the small domain of LcTS, and is within 4.5 A 
of this region. 
Although the molecules from the in-parallel optimization 
had higher affinities for LcTS than did the lead compounds, 
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Figure 6 
A docked orientation of didansyltyrosine (21 B) in LcTS showing the fit 
to the overall binding site (colored as in Figure 1). The molecular 
surface of the enzyme is shown in gray, except for Lys50, which is 
colored in blue. Several key residues are labeled. 
they were also larger and more hydrophobic. To examine 
whether the affinity of these compounds correlated with 
their hydrophobicity, the IogP of the compounds was calcu- 
lated [34]. We observed no correlation between affinity and 
hydrophobicity using this measure (data not shown). To 
investigate how specificity for LcTS changed with affinity 
in the dansyltyrosine family, the activity of these com- 
pounds was measured against human TS (HTS), the folate- 
converting enzyme dihydrofolate reductase (DHFR), and 
chymotrypsin, which recognizes hydrophobic ligands [35] 
(Figure 7). The lead compound, dansylhydrazine, is 13-fold 
less selective for LcTS than for HTS. Dansyltyrosine, on 
the other hand, is fivefold more selective for LcTS than for 
HTS but still has an IC,,, of 50 PM for chymotrypsin, which 
is threefold better than for LcTS. Finally, didansyltyrosine 
is 30-fold more selective for LcTS than for HTS and Z-fold 
more selective for LcTS than for chymotrypsin. The K, 
values of folate for HTS and LcTS are both around 10 @I, 
so that the IC,, ratios (Figure 7) probably reflect K, ratios, 
although we have not measured Ki values for HTS directly. 
None of the three compounds shows any affinity for DHFR 
at the maximum concentrations allowed by solubility. In the 
dansyltyrosine family of LcTS inhibitors. specificity and 
affinity appear to rise together. 
Discussion 
Our interest was to probe a substrate-binding site for its 
ability to bind new inhibitors in a manner that allowed 
rapid elaboration of a lead compound. It is appropriate to 
ask whether didansyltyrosine and its congeners are gen- 
uinely binding at the folate site of LcTS, and whether 
they are doing so in a specific manner. I f  the didansylty- 
rosines are binding specifically to the folate site, how dif- 
ferent are they from the substrate and known antifolates, 
that is, are they genuinely novel? 
Didansyltyrosine (21B) inhibits LcTS competitively 
with CH,-H,folate (Figure 4) and noncompetitively with 
the nucleotide substrate dUMP, as does its analog 20B 
Figure 7 
r 104 
1 
2 100: 
- 
10: 
1 
Dansylhydrazine Dansyltyrosine Didansyltyrosine 
Compound 
Chemstry & Bdogy 
The specificity of the dansyltyrosine analogs for LcTS versus HTS and 
chymotrypsin. Activity against LcTS (red), HTS (blue) and 
chymottypsin (gray). 
and as does dansyltyrosine itself. W’e suspect that most of 
the in-parallel library members would show the same 
behavior. These kinetic data do not prove that the 
inhibitors are binding at the folate site; formally, compet- 
itive inhibition only implies binding to the same state of 
the enzyme to which the folate binds. Still, it seems 
likely that didansyltyrosine binds to the closed confor- 
mation of LcTS at the folate site, given this inhibition 
pattern. Even inhibitors that bind only partially to the 
folate site, such as phenolphthalein, show a mixed inhi- 
bition pattern versus CH2-H,folate [18]. 
One indication of specific binding is that small changes 
among the dansyltyrosine derivatives can have a large 
effect on activity (Table 3). For instance, converting a sul- 
fonamide into an amide (compound 16B versus lSB, or 
20B versus 22B) diminishes activity by sixfold to 15fold. 
In a larger change, adding an isoxazole ring to 1B (to make 
compound 4B) improved affinity tenfold. Although larger 
derivatives are often more active than the smaller ones, 
neither size nor hydrophobicity is enough to explain 
binding; there is no correlation between binding affinity 
and ClogP value. For instance, the amide analogs have 
higher ClogP values but are considerably less potent than 
their sulfonamide congeners. Similarly, compound 29B 
(ClogP 5.2) is less hydrophobic but more active than the 
similar inhibitors 288 (ClogP 6.2), 30B (ClogP 7.0), and 
31B (ClogP 9.3). Not every large change led to a signifi- 
cant effect, however. For example, compound 33B has 
almost the same affinity for LcTS as does compound ZSB, 
even though a third ring has been added to the former. 
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Some of the functionality explored in these compounds 
might well be only loosely associated with the enzyme. 
Although there is no overall correlation between 
hydrophobicity and activity, the most active inhibitor, 
didansyltyrosine (ZlB), is among the most hydrophobic. 
Often, a substrate can be turned into an inhibitor, or an 
inhibitor made more potent, by adding large hydrophobic 
groups to a core scaffold. This can reduce specificity for 
related receptors or enzymes [36]. Because our interest 
was to explore the chemical diversity allowed within a par- 
ticular site, it seemed prudent to investigate how the 
specificity of the dansyl derivatives related to their affinity 
for LcTS. Moving from the initial, low-affinity lead com- 
pound dansylhydrazine to the more active dansyltyrosine 
and finally to didansyltyrosine, specificity for LcTS 
improved over 400-fold versus the highly related enzyme 
HTS. Specificity for LcTS improved by two orders of 
magnitude versus the hydrophobic recognizing enzyme 
chymotrypsin [35] (Figure 7). In other docking studies, we 
have found that hydrophobic ligands will often inhibit 
chymotrypsin (data not shown), making this a useful, if 
not decisive, control for this series of inhibitors. The 
elaboration of the lead compound resulted in not only 
more potent inhibitors, but also more specific inhibitors. 
This is consistent with binding at a specific site on LcTS. 
Didansyltyrosine (21B) is more specific for LcTS than are 
most antifolates which typically show little specificity for 
TS enzymes from different species [37,38]. 
Didansyltyrosine (21B) appears to bind specifically to 
LcTS, and it would be interesting to understand the partic- 
ular interactions that it makes with the enzyme. To model 
these interactions, we docked multiple conformations of 
didansyltyrosine into LcTS, and looked for conformations 
with favorable fits that could also explain the 
structure-activity data. Therle is considerable overlap 
between the docked orientations of didansyltyrosine and 
the crystallographic orientation of CB3717 (Figure 5). The 
docked conformations usually bury the first, O-linked 
dansyl ring in the quinazoline-binding site of LcTS, consis- 
tent with the anchor role of this ring in the structure-activ- 
ity experiments. In these orientations, the dansyl moiety 
makes nonpolar interactions with dUMP, suggesting that 
dUMP would be able to form a ternary complex with LcTS 
and didansyltyrosine. The first dansyl ring also interacts 
with active-site residues such as Ile81, Ala315 and Leu195. 
Most docked orientations appear to form interactions 
between the tyrosine ring of didansyltyrosine (21B) and 
Phe228 and Leu224 of LcTS (Figure 5). 
The active site, which is constricted in the quinazoline- 
binding site, opens up in the region where the second 
dansyl ring docks, and the docking program finds several 
high scoring, dissimilar fits for this inhibitor moiety. Many 
orientations bury this dansyl ring against nonpolar surface 
area in the LcTS structure, consistent with the high affinity 
of this hydrophobic sidechain. Two such nonpolar patches 
stand out: that defined by Ala309 and Leu310 (Figure Sa), 
and that defined by Leu56, Ile81 and the CD of His80. We 
cannot reliably distinguish between these orientations on 
the basis of docked energies alone [39]. Considering the 
structure-activity data of the ligands, orientations that fit 
the second dansyl ring against the nonpolar patch defined 
by Leu56 and Ile81 are consistent with some of the varia- 
tions that we observe. For instance, there is little room for 
large substitutions off the dimethyl amino group of the 
second dansyl ring in this orientation. This would explain 
the lower activity of the dibutyl derivative (31B), and com- 
pounds 26B and 27B, all of which would have steric clashes 
with enzyme residues in this orientation. 
No single docked orientation of didansyltyrosine explains 
all of the binding data. For instance, it is not clear why the 
affinity of 4B is l&fold higher than 3B (Table 3). Simi- 
larly, the docked structures do not explain why the sulfon- 
amide inhibitors should always bind better than their 
amide analogs (Table 3). Partly, these ambiguities reflect 
the ‘low resolution’ accuracy of our docking algorithm [39], 
which can sometimes correctly predict the gross features of 
a binding complex, such as the overall placement of a ring, 
but miss detailed features, such as hydrogen bonding and 
conformational accommodation [l&40]. Partly, these ambi- 
guities might be due to the genuine ability of different 
didansyltyrosine analogs to occupy different configurations 
in the LcTS- binding site. Such multiple binding modes 
have been reported previously for other inhibitor classes 
for this enzyme [41,42]. A very detailed description of the 
binding of didansyltyrosine with LcTS awaits an experi- 
mental structure determination. For now, several features 
could be summarized from the docking and 
structure-activity studies. The didansyl tyrosine analogs 
appear to bind in the folate-binding site of LcTS, with the 
first, O-linked dansyl ring in about the same position as the 
quinazoline ring of CB3717, interacting with dUMP and 
folate-binding residues. The tyrosine ring of the inhibitors 
appears to interact with residues Phe228 and LeuZ24. The 
docking studies allow the second, ,V-linked dansyl ring to 
be in several positions; we favor those that place it in 
hydrophobic patches such as that defined by Ala309 and 
Leu310, or that defined by Leu56 and Ile81. 
As a final question, it is appropriate to ask how different 
are the dansyltyrosine analogs from known antifolates. In 
Figure 8 we present several known antifolates and the 
substrate CH,-H,folate, alongside didansyltyrosine. 
Without resorting to diversity metrics, it can be seen that 
the dansyltyrosine analogs differ from the classical antifo- 
lates, such as CB3717 and ZD1694. The dansyltyrosines 
lack the quinazoline ring that is highly conserved among 
most antifolate inhibitors of TS, and they do not possess a 
glutamic acid peptide tail. 
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Didansyltyrosine (21 B)
Comparing the structure of didansyl tyrosine
to known inhibitors of TS.
Molecules that bear little resemblance to substrates can
bind to the folate site of LeTS. This is consistent with
earlier results with non-antifolate inhibitors of HTS [1,18].
Although LeTS is in many ways a highly specific enzyme
[27,43], the folate site can recognize different inhibitor
scaffolds. More broadly, these results are consistent with
recent structural and screening work, in which diverse
ligands have been found to bind at conserved ligand-
recognition sites in proteins [1,24,44,45]. Substrate sites
on enzymes might allow considerable diversity among
inhibitor molecules.
As a technical matter, combining structure-based discov-
ery with in-parallel synthetic elaboration exploits the
complementarity between the two techniques. Previous
studies have shown that structural data can constrain
and guide the combinatorial elaboration of known lead
compounds [5,6]. Here we drew on the ability of mol-
ecular docking to discover a new scaffold and then used
in-parallel techniques to elaborate upon it rapidly. Our
combination of the two techniques was crude - we
merely insisted that any lead compound have a chem-
istry that would allow in-parallel elaboration and then
used the enzyme structure as guide to model increas-
ingly complex inhibitors. More sophisticated algorithms
for combining structure-based discovery with explo-
ration of diversity are being investigated in several labo-
ratories; this pilot study suggests that such algorithms
might be practical.
Significance
Substrate sites on enzymes are attractive targets for
structure-based inhibitor design. Two difficulties hinder
efforts to discover and elaborate new inhibitors that bind
at these sites. First, nonsubstrate-like inhibitors often
bind at nonsubstrate sites. Second, novel scaffolds fre-
quently introduce chemistry that is unfamiliar, making
synthetic elaboration challenging. In an effort to discover
and elaborate a new scaffold for a substrate site, we com-
bined molecular docking with in-parallel synthetic elabo-
ration. We targeted the folate-binding site of thymidylate
synthase, from Lactobacillus casei, which has been well-
studied for structure-based drug design. TS catalyzes the
final step on the biosynthetic pathway to thymidylate,
and is consequently a target for proliferative diseases.
The site was found to recognize molecules that were dis-
similar to the folate substrate. Dansyltyrosine derivatives
have no obvious similarity to the cognate ligand but nev-
ertheless bind to L. casei thymidylate synthase (LeTS)
with micromolar affinities. Small differences between
related analogs can have significant effects on binding.
Higher affinity is correlated with greater specificity for
LcTS versus related enzymes. Nonfolate analog
inhibitors have also been found to bind in the folate site
of human thymidylate synthase (HTS) [1], and diverse
ligands have been found to bind at conserved ligand
recognition sites in other proteins [24,44,45]. Even at
substrate sites, at least in some proteins, several funda-
mentally different chemical scaffolds can be recognized.
Research Paper Structure-based discovery and in-parallel optimization of thymidylate synthase inhibitors Tondi et al. 329 
In-parallel and combinatorial synthetic techniques seem 
complementary to structure-based methods. Studies 
from several groups suggest that structural information 
can usefully constrain the diversity available in combina- 
torial explorations of known lead compounds 1561. We 
used a simple approach to combine the two techniques to 
explore the chemistry of a new scaffold. More automated 
methods can be envisaged. 
Materials and methods 
Computational work 
The structure of LcTS in complex with dUMP and CB3717 (a 
5,10-propargyl-quinazoline derivative of folate) was used as the basis for 
computational studies 1301. Potential binding sites for ligand atoms were 
defined by a set of 64 atoms from the folate analog CB3717 and phe- 
nolphthalein 1181 from their respective complexes with LcTS. The phe- 
nolphthalein coordinates were generated in the TS ternary complex site 
by rigid-body fitting the Co. atoms of the phenolphthalein complex with 
LcTS onto the CB3717 Ca coordinates. Four of the phenolphthalein 
atoms were not used because of bad contacts with the protein in its 
ternary complex conformation. All bound water molecules were deleted, 
We explored the active site of the enzyme with a modified version of 
DOCK3.5 [32] and a 153,516 subset of the ACD/95.2 database of 
commercially available compounds (MDL Inc, San Leandro CA). Partial 
atomic charges and van der Waals parameters for each database mol- 
ecule were calculated [31 I. Approximately 500 orientations were calcu- 
lated for each database molecule. Each orientation of each ligand was 
filtered for steric fit to LcTS with a DISTMAP grid 1461 with polar and 
nonpolar contact limits of 2.4 A and 2.8 A, respectively. Close contacts 
were disallowed. Orientations that passed this steric filter underwent 
up to 250 steps of simplex minimization [47] using a van der Waals 
and an electrostatic potential as calculated by CHEMGRID [31] and 
Delphi [48], respectfully. Energies of interaction were corrected for 
ligand desolvation energies [32]. The calculation took four CPU days 
on a 250 Mhz Indigo2 R4400 SGI workstation. 
Complexes for the best-scoring 400 compounds were evaluated using 
MIDAS-Plus [49]. On the basis of the IDOCK score, the number of spe- 
cific interactions with the protein, and the ease of synthetic elaboration, 
five compounds were tested for the ability to inhibit LcTS (Table 1). To 
allow more detailed structural modeling, multiple conformations of dan- 
syltyrosine and didansyltyrosine (21 B) were generated using SYBYL 
6.3 (Tripos, St. Louis MO) and docked into LcTS. Conformations were 
generated by rotating all single, nonterminal bonds in increments of 
120” [33]. Each conformer was independently docked as above. The 
hydrophobicity of the R groups in compounds 1 B to 348 (Table 3) was 
calculated using the ClogP method [34]. 
Synthetic chemistry 
/V-Fmoc-tyrosine was purchased from Advanced ChemTech; N-Boc- 
tyrosine, sulfonyl chlorides and acid chlorides were purchased from 
Aldrich, Maybridge International, TCI-US and Lancaster. TentaGel S 
PHB-Wang equivalent resin (OH, 0.24 mmol/g), Tentagel Rink Amide 
(NH2, 0.26 mmol/g) and Rink Amide (NH2, 0.81 mmol g) resins 1501 
were purchased from Advanced Chemtech. The purity of all synthesized 
compounds was determined by using thin layer chromatography (TLC) 
and high performance liquid chromatography (HPLC). For TLC, 250 nm 
silica gel precoated uniplates (Analtech) were used with the appropriate 
solvent system. The chromatograms were visualized at 254 nm. HPLC 
was performed on a Rainin instrument using a Spheri-5 Cyano 5 micron 
cartridge (220 x 4.6 mm) at flow rate 0.8 mllmin; UV detection was at 
300 nm, and solvents (A; 0.1% trifloluroacetic acid in water) and (B; 
0.08% triflouroacetic acid in acetonitrile/water; 9:l; gradient 10% to 
900/o B in 25 min). Structures were characterized using nuclear mag- 
netic resonance (NMR) spectroscopy and mass spectrometry (see the 
Supplementary material section). 
The synthesis of 22 dansyl amino derivatives (Table 2) was accom- 
plished in liquid phase (see the Supplementary materials section). The 
in-parallel synthesis was carried out on an Advanced ChemTech 357 
MPS using solid-phase methods (Figure 3, Table 3). N-Fmoc-O-dansyl- 
tyrosine was loaded on the Wang Resin-OH as described [51]. The 
synthesis was carried out using 4.25 g (1.02 mmol) of the TentaGel 
Wang Resin that was pre-washed with dry dichlormethane (DCM) 
three times. The dry N-Fmoc-dansyltyrosine (3 eq., 3.06 mmol, 
1.955 g), was dissolved in DCM with I-methyl-imidazole (2.25 eq., 
2.29 mmol) in a septum-stoppered flask. The solution was then trans- 
ferred to a stoppered flask containing MSNT (3 eq., 3.06 mmol, 
0.816 g) in DCM, and the mixture was added to the hydroxymethyl poly- 
styrene support Wang resin. The first coupling was carried out with 
continuous mixing for 3 h. Reactants were washed out first with 
dimethylformamide (DMF) and then with DCM. A second coupling with 
fresh reagents was performed for 2 h under the same conditions. The 
resin was divided in the 34 vessels and washed twice with DMF and 
DCM. The resin was then reacted with acetic anhydride and diisopropy- 
lethylamine (DIEA) (tenfold excess) in DCM for 1 h to cap the unreacted 
hydroxyl groups on the resin (the loading was determined based on the 
UV absorption of the dibenzofulvene group after Fmoc deprotection). 
The Fmoc group was deprotected with 30% v/v piperidine (PIP)/DMF 
for 3 min followed by another treatment with fresh reagent for 12 min. 
After washing with DMF (1 min), methanol (1 min), DMF (1 min), and 
NMP (1 min), the 0-dansyltyrosine-carboxy-resin was reacted with 34 
different sulfonyl chloride or carbonyl chloride groups. The reaction was 
carried out with three equivalents of R sulfonyl chloride or R carbonyl 
chloride and six equivalents of DIEA in NMP. After washing twice with 
DMF, three times with methanol and drying the resin under vacuum, all 
compounds were cleaved from the resin by treatment with trifluo- 
roacetic acid (TFA) for 2 h. The resin was then washed several times 
with acetic acid and DCM. The solution containing the compound was 
concentrated and dried. The purity of each product was determined 
using HPLC and structure confirmed using H-NMR and mass spec- 
troscopy (see the Supplementary material section). 
Enzymology 
LcTS was heterologously expressed and purified [52]; the enzyme was 
greater than 95% homogenous as determined using sodium dodecyl- 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Purified 
enzyme was stored at -80°C in 1 mM phosphate buffer, pH 7.0, 
0.1 mM EDTA. Stock solutions of the inhibitors were prepared in 
DMSO and stored at -20%. The inhibitory activity of the compounds 
versus TS was determined by enzyme assay. The assays were per- 
formed spectrophotometrically by following the absorbance at 340 nm, 
which increases during the TS catalyzed reaction due to the oxidation 
of CH,-H,folate to dihydrofolate. These assays were performed in a 
Hewlett Packard 8453 UV spectrophotometer equipped with a multi- 
cell transporter and thermostated with a circulating bath. Assays were 
performed at 20°C in the standard assay buffer, which contained 
50 mM TES at pH 7.4, 25 mM MgCI,, 6.5 mM formaldehyde, 1 mM 
EDTA and 75 mM 2-mercaptoethanol. For IC50 calculations, assays 
were performed with 80uM dUMP, 0.03uM TS and 30uM 
CH,-H,folate. For the K, calculations the CH,-H,folate was varied 
from 20 uM to 120 PM. The inhibition pattern against dUMP was mea- 
sured by varying dUMP between 56 uM and 178uM with 
CH,-H,folate held constant at 32 pM. Reactions were initiated by the 
addition of enzyme. The K, values were calculated by plotting the 
slopes from Lineweaver-Burk analyses versus inhibitor concentration 
(e.g., Figure 4) [53]. The IC,, values were determined by plotting the 
inverse of the initial velocity against concentration of inhibitor [53]. HTS 
was purified using affinity column chromatography [54]. The enzyme 
was greater than 95% homogeneous by SDS-PAGE. HTS was used 
immediately after purification. 
DHFR (EC 1.5.1.3) from bovine liver (Sigma Chemical, St. Louis MO) 
assays were monitored spectrophotometrically by measuring the 
decrease in absorbance at 340 nm upon NADPH reduction. Assays were 
conducted in 50 mM TES, 1 mM EDTA and 75 mM P-mercaptoethanol, 
330 Chemistry & Biology 1999, Vol 6 No 5 
pH 7 at 25°C. NADPH was used at a concentration of 100 PM, the dihy- 
drofolate concentration was 58 wM, and 0.011 units of enzyme were 
used per assay (1 unit is the amount required to reduce 1 nmol of dihy- 
drofolate per minute). Assays were initiated with enzyme. Dimethyl sul- 
foride (DMSO) was used to deliver inhibitor; the DMSO never exceeded 
1 Oo/, of the reaction volume. 
Bovine pancreatic cc-chymotrypsin (Sigma) assays were performed by 
monitoring the hydrolysis of N-benzoyl-I-tyrosine ethyl ester (Sigma) 
[55]. All assays were initiated with enzyme. DMSO was used to deliver 
the inhibitor and never exceeded 5% of the total reaction volume. 
Supplementary material 
Additional details on liquid phase syntheses, NMR and MS analyses 
are published with the online version of this paper. 
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